Literature DB >> 33467585

The Prognostic Value of Eosinophil Recovery in COVID-19: A Multicentre, Retrospective Cohort Study on Patients Hospitalised in Spanish Hospitals.

María Mateos González1, Elena Sierra Gonzalo2, Irene Casado Lopez1, Francisco Arnalich Fernández3, José Luis Beato Pérez4, Daniel Monge Monge5, Juan Antonio Vargas Núñez6, Rosa García Fenoll7, Carmen Suárez Fernández8, Santiago Jesús Freire Castro9, Manuel Mendez Bailon10, Isabel Perales Fraile11, Manuel Madrazo12, Paula Maria Pesqueira Fontan13, Jeffrey Oskar Magallanes Gamboa14, Andrés González García15, Anxela Crestelo Vieitez16, Eva María Fonseca Aizpuru17, Asier Aranguren Arostegui18, Ainara Coduras Erdozain19, Carmen Martinez Cilleros20, Jose Loureiro Amigo21, Francisco Epelde22, Carlos Lumbreras Bermejo23, Juan Miguel Antón Santos1.   

Abstract

OBJECTIVES: A decrease in blood cell counts, especially lymphocytes and eosinophils, has been described in patients with serious Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), but there is no knowledge of their potential role of the recovery in these patients' prognosis. This article aims to analyse the effect of blood cell depletion and blood cell recovery on mortality due to COVID-19.
DESIGN: This work was a retrospective, multicentre cohort study of 9644 hospitalised patients with confirmed COVID-19 from the Spanish Society of Internal Medicine's SEMI-COVID-19 Registry.
SETTING: This study examined patients hospitalised in 147 hospitals throughout Spain. PARTICIPANTS: This work analysed 9644 patients (57.12% male) out of a cohort of 12,826 patients ≥18 years of age hospitalised with COVID-19 in Spain included in the SEMI-COVID-19 Registry as of 29 May 2020. MAIN OUTCOME MEASURES: The main outcome measure of this work is the effect of blood cell depletion and blood cell recovery on mortality due to COVID-19. Univariate analysis was performed to determine possible predictors of death, and then multivariate analysis was carried out to control for potential confounders.
RESULTS: An increase in the eosinophil count on the seventh day of hospitalisation was associated with a better prognosis, including lower mortality rates (5.2% vs. 22.6% in non-recoverers, OR 0.234; 95% CI, 0.154 to 0.354) and lower complication rates, especially regarding the development of acute respiratory distress syndrome (8% vs. 20.1%, p = 0.000) and ICU admission (5.4% vs. 10.8%, p = 0.000). Lymphocyte recovery was found to have no effect on prognosis. Treatment with inhaled or systemic glucocorticoids was not found to be a confounding factor.
CONCLUSION: Eosinophil recovery in patients with COVID-19 who required hospitalisation had an independent prognostic value for all-cause mortality and a milder course.

Entities:  

Keywords:  2019-nCoV; COVID-19; SARS-CoV-2; coronavirus; eosinophil; prognosis

Year:  2021        PMID: 33467585      PMCID: PMC7830154          DOI: 10.3390/jcm10020305

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  37 in total

Review 1.  TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties.

Authors:  T R Mosmann; R L Coffman
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

Review 2.  Plasticity of CD4+ T cell lineage differentiation.

Authors:  Liang Zhou; Mark M W Chong; Dan R Littman
Journal:  Immunity       Date:  2009-05       Impact factor: 31.745

3.  Eosinophils: Ancient Cells with New Roles in Chronic Lung Inflammation.

Authors:  Kewal Asosingh; Mark A Aronica
Journal:  Am J Respir Crit Care Med       Date:  2017-05-15       Impact factor: 21.405

4.  The table 2 fallacy: presenting and interpreting confounder and modifier coefficients.

Authors:  Daniel Westreich; Sander Greenland
Journal:  Am J Epidemiol       Date:  2013-01-30       Impact factor: 4.897

5.  Eosinophils and eosinophil-associated diseases: An update.

Authors:  Jeremy A O'Sullivan; Bruce S Bochner
Journal:  J Allergy Clin Immunol       Date:  2017-10-16       Impact factor: 10.793

6.  Eosinopenia and COVID-19.

Authors:  Fahmina Tanni; Eleonora Akker; Muhammad M Zaman; Nilka Figueroa; Biju Tharian; Kenneth H Hupart
Journal:  J Am Osteopath Assoc       Date:  2020-07-16

Review 7.  COVID-19 Outbreak: An Overview.

Authors:  Marco Ciotti; Silvia Angeletti; Marilena Minieri; Marta Giovannetti; Domenico Benvenuto; Stefano Pascarella; Caterina Sagnelli; Martina Bianchi; Sergio Bernardini; Massimo Ciccozzi
Journal:  Chemotherapy       Date:  2020-04-07       Impact factor: 2.544

8.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

9.  Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China.

Authors:  J Zhang; X Wang; X Jia; J Li; K Hu; G Chen; J Wei; Z Gong; C Zhou; H Yu; M Yu; H Lei; F Cheng; B Zhang; Y Xu; G Wang; W Dong
Journal:  Clin Microbiol Infect       Date:  2020-04-15       Impact factor: 8.067

10.  Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis.

Authors:  Zhaohai Zheng; Fang Peng; Buyun Xu; Jingjing Zhao; Huahua Liu; Jiahao Peng; Qingsong Li; Chongfu Jiang; Yan Zhou; Shuqing Liu; Chunji Ye; Peng Zhang; Yangbo Xing; Hangyuan Guo; Weiliang Tang
Journal:  J Infect       Date:  2020-04-23       Impact factor: 6.072

View more
  11 in total

1.  Intermediate Monocytes with PD-L1 and CD62L Expression as a Possible Player in Active SARS-CoV-2 Infection.

Authors:  Elżbieta Rutkowska; Iwona Kwiecień; Krzysztof Kłos; Piotr Rzepecki; Andrzej Chciałowski
Journal:  Viruses       Date:  2022-04-15       Impact factor: 5.818

2.  A safe protocol to identify low-risk patients with COVID-19 pneumonia for outpatient management.

Authors:  Francisco Javier Teigell Muñoz; Elena García-Guijarro; Paula García-Domingo; Guadalupe Pérez-Nieto; Fernando Roque Rojas; María García-Peña; María Antonia Nieto Gallo; José Antonio Melero Bermejo; María Teresa de Guzman García-Monge; Juan José Granizo
Journal:  Intern Emerg Med       Date:  2021-02-23       Impact factor: 3.397

3.  Long-Term Follow-Up of a Severe Eosinophilic Asthmatic Patient With Comorbid Nasal Polyposis Hospitalized for SARS-CoV-2 Infection While Receiving Benralizumab: A Case Report.

Authors:  Annamaria Ambrosino
Journal:  Cureus       Date:  2021-12-12

4.  Curing Cats with Feline Infectious Peritonitis with an Oral Multi-Component Drug Containing GS-441524.

Authors:  Daniela Krentz; Katharina Zenger; Martin Alberer; Sandra Felten; Michèle Bergmann; Roswitha Dorsch; Kaspar Matiasek; Laura Kolberg; Regina Hofmann-Lehmann; Marina L Meli; Andrea M Spiri; Jeannie Horak; Saskia Weber; Cora M Holicki; Martin H Groschup; Yury Zablotski; Eveline Lescrinier; Berthold Koletzko; Ulrich von Both; Katrin Hartmann
Journal:  Viruses       Date:  2021-11-05       Impact factor: 5.048

5.  [Screening for strongyloidiasis in Spain in the context of the SARS-CoV-2 pandemic: results of a survey on diagnosis and treatment].

Authors:  Azucena Rodríguez-Guardado; Miriam J Álvarez-Martínez; María Delmans Flores; Elena Sulleiro; Diego Torrús-Tendero; María Velasco; Francisco Javier Membrillo
Journal:  Enferm Infecc Microbiol Clin       Date:  2021-12-15       Impact factor: 1.731

6.  COVID-19, Eosinophils, and Biologicals for Severe Asthma.

Authors:  Carlo Lombardi; Diego Bagnasco; Giovanni Passalacqua
Journal:  Front Allergy       Date:  2022-04-28

7.  Association between the peripheral blood eosinophil counts and COVID-19: A meta-analysis.

Authors:  Rong Huang; Liangcai Xie; Junpeng He; Hong Dong; Tianchun Liu
Journal:  Medicine (Baltimore)       Date:  2021-06-11       Impact factor: 1.817

Review 8.  Immunological effects of convalescent plasma therapy for coronavirus: a scoping review.

Authors:  Behnaz Esmaeili; Shahnaz Esmaeili; Zahra Pourpak
Journal:  BMC Infect Dis       Date:  2021-12-24       Impact factor: 3.090

9.  Association of Peripheral Blood Parameters With Outcomes of COVID-19 Infection in a Tertiary Care Setting of Eastern India: An Institute-Based Study.

Authors:  Jitendra S Nigam; Anup Kumar; Ruchi Sinha; Haripriya H; Neeraj Kumar; Tarun Kumar; Shreekant Bharti; Punam P Bhadani
Journal:  Cureus       Date:  2021-12-27

10.  Utility of Coronavirus Disease 2019 Immune Profiling for the Clinician at the Bedside.

Authors:  Samuel J Minkove; Parizad Torabi-Parizi
Journal:  Crit Care Med       Date:  2021-10-01       Impact factor: 9.296

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.